Many re­searchers be­lieve can­cer cell ther­a­pies called CAR-Ts could shift the treat­ment par­a­digm for pa­tients with au­toim­mune dis­ease. But three re­cent­ly dis­closed deaths in No­var­tis’...

Three pa­tients died in No­var­tis tri­als of its CD19-di­rect­ed CAR-T treat­ment fol­low­ing a dan­ger­ous im­mune sys­tem re­sponse, and a sim­i­lar ther­a­py from Bris­tol My­ers Squibb...

The dream of mak­ing per­son­al­ized ge­net­ic med­i­cines at a mo­ment’s no­tice just got a ma­jor in­fu­sion of fund­ing from the fed­er­al gov­ern­ment.

Five groups were...

Plus, news about Novone­sis, As­pen, Fortrea and North­way.

Al­teogen and No­var­tis make a deal: The Swiss phar­ma is li­cens­ingAl­teogen’s hyaluronidase en­zyme, called ALT-B4, which...

Pres­i­dent Don­ald Trump an­nounced vol­un­tary drug pric­ing deals with nine new com­pa­nies on Mon­day, for the first time veer­ing out­side of the orig­i­nal crop of...

Nine new com­pa­nies have an­nounced vol­un­tary drug pric­ing deals with the White House, look­ing to avoid in­dus­try tar­iffs and in­clu­sion in two CMS pi­lot pro­grams...